A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NYU Langone Health
M.D. Anderson Cancer Center
Nationwide Children's Hospital
SCRI Development Innovations, LLC
University of Colorado, Denver
Emory University
Columbia University
University of Southern California
Abramson Cancer Center at Penn Medicine
Dana-Farber Cancer Institute
Weill Medical College of Cornell University
University Health Network, Toronto
Jonsson Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Tang-Du Hospital
Australasian Leukaemia and Lymphoma Group
Herlev Hospital
The First Affiliated Hospital of Soochow University
Nantes University Hospital
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
First Affiliated Hospital of Zhejiang University
Peking University Third Hospital
Beni-Suef University
Herlev Hospital
Medical College of Wisconsin
University of Michigan Rogel Cancer Center
University of Pennsylvania
Emory University
Herlev Hospital
Washington University School of Medicine
University of Michigan Rogel Cancer Center
Washington University School of Medicine
Leiden University Medical Center
University of North Carolina, Chapel Hill